Arrowpoint Investment Partners Singapore Pte. Ltd. Takes $527,000 Position in Omnicell, Inc. $OMCL

Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,630 shares of the company’s stock, valued at approximately $527,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in shares of Omnicell in the second quarter valued at approximately $26,000. Clearstead Advisors LLC raised its position in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. First Horizon Corp raised its position in shares of Omnicell by 54.6% in the fourth quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after purchasing an additional 564 shares during the period. LSV Asset Management bought a new stake in shares of Omnicell in the third quarter valued at approximately $97,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after purchasing an additional 3,932 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Omnicell stock opened at $43.60 on Friday. The firm’s 50 day simple moving average is $39.70 and its 200 day simple moving average is $41.31. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.98 billion, a PE ratio of 99.09, a price-to-earnings-growth ratio of 1.08 and a beta of 0.97. Omnicell, Inc. has a 1-year low of $26.84 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. Omnicell’s revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 EPS. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Omnicell news, EVP Corey J. Manley sold 7,405 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the transaction, the executive vice president owned 96,717 shares of the company’s stock, valued at $3,355,112.73. The trade was a 7.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 15,520 shares of company stock valued at $607,610. Corporate insiders own 2.92% of the company’s stock.

Analyst Ratings Changes

OMCL has been the topic of several research reports. Weiss Ratings raised shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Zacks Research raised shares of Omnicell from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Finally, UBS Group set a $60.00 target price on shares of Omnicell and gave the stock a “buy” rating in a report on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $59.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.